Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the safety and efficacy of administration of intratumoral IP-001 injection at different dosages (volume and concentration) following local microwave ablation (MWA) or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub starszy
- •Potwierdzony diagnozą raka wątroby (HCC) - badania obrazowe lub biopsja
- •Planowany zabieg usunięcia guza lub zniszczenia go mikrofalami
- •Rak wątroby ze średnim, wysokim lub bardzo wysokim ryzykiem powrotu choroby
- •Rak tylko w wątrobie - bez przerzutów poza wątrobę większych niż 1 cm
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Jeśli w przeszłości miał zapalenie wątroby C - musi być leczone co najmniej 1 miesiąc przed badaniem
- •Jeśli ma zapalenie wątroby B - musi być kontrolowane lekami przez co najmniej 4 tygodnie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Louisville
Louisville, United States
Trial contact
Robert Martin, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.